Search Results

Collagen Matrix, Inc., a global leader in regenerative medicine and a Linden Capital Partners portfolio company, announced the acquisition of Polyganics, B.V. Polyganics is a medical technology company that develops and manufactures bioresorbable medical devices.

Polyganics announced that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect.

Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation of its Liver and Pancreas Sealant Patch.

Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has announced positive data from its ENCASE I* clinical trial.

Randomized controlled trial in the US and Europe will enable LIQOSEAL® to be submitted for FDA approval

Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, is expanding its capacity with a new facility at the Zernike Campus, Groningen, to enter a new phase of commercial and R&D growth.

Polyganics announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch.

Polyganics today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.

Polyganics today announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL®, its dura sealant patch. The self-adhesive patch has been developed to reduce cerebrospinal fluid (CSF) leakage following brain surgery.

The grant, together with contributions from the city and province of Groningen, totals EUR 1.2 million.